Skip to main content
logo
TScan Therapeutics logo
TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
0.2393
+0.0287 (13.63%)
At close: Oct 15, 2026, 4:00 PM EDT
0.2336
-0.0057 (-2.38%)
After-hours: Oct 15, 2026, 5:15 PM EDT

TScan Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
7.1110.332.8221.0513.5410.14
Revenue Growth
2.15%266.65%-86.62%55.52%33.47%834.65%
Gross Profit
-88.32-102.23-104.53-67.1-46.28-34.81
Operating Income
-118.54-133.81-134.82-93.46-66.64-48.64
Net Income
-117.71-129.77-127.5-89.22-66.22-48.63
Earnings Per Share
-1.74-2.28-2.25-1.87-2.75-4.17
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
100.16152.41290.11192.04120.03161.41
Total Debt
90.8994.1497.3892.4385.986.04
Net Cash (Debt)
9.2658.27192.7399.6134.04155.36
Net Cash Growth
-92.37%-69.77%93.48%192.60%-78.09%467.91%
Net Cash Per Share
0.141.023.412.081.4213.32

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-116.28-135.32-110.82-61.36-66.5-48.68
Capital Expenditures
-2.16-4.41-3.83-3.15-4.23-9.94
Free Cash Flow
-118.44-139.73-114.65-64.5-70.73-58.62
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Margin
-1667.02%-1296.01%-4787.68%-444.00%-492.32%-479.65%
Pretax Margin
-1655.35%-1256.81%-4527.66%-423.86%-489.26%-479.49%
Profit Margin
-1655.35%-1256.81%-4527.66%-423.86%-489.26%-479.49%
FCF Margin
-1665.57%-1353.28%-4071.27%-306.45%-522.56%-578.03%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
2.285.5061.0013.252.7610.54